FDA Updates Highlighting the Latest Cancer Treatments : Oncology Times
An abstract is unavailable.
An abstract is unavailable.
Matthew S. Johnson, MD, discusses a pilot study of Y-90 radioembolization plus pembrolizumab in patients with poor-prognosis hepatocellular carcinoma.
Idalid Franco, MD, MPH, discusses the integration of immunotherapy, molecular biomarkers, and risk factors for recurrence into the endometrial cancer paradigm.
surgeons as to patient preferences, the rate at which they are available and disparities in ACP completion are still not understood. The objective of this…
The FDA granted accelerated approval to tovorafenib for pediatric patients relapsed/refractory low-grade glioma with a BRAF fusion/rearrangement or a BRAF V600 mutation.
An abstract is unavailable.
The FDA has approved lutetium Lu 177 dotatate for pediatric patients 12 years of age and older with SSTR)–positive GEP-NETs.
An abstract is unavailable.
After noticing a lump on the right side of his neck, Chu Nguyen, Ph.D., came to MD Anderson for a second opinion. Further testing revealed…
The field of central nervous system (CNS) oncology is rapidly changing with advances in molecular diagnostics. The therapeutic implications are being realized …
An abstract is unavailable.